Archive - Drug Development Executive

State Of The Art in SLE: For Biotech CMOs and CSOs

Jul 18 •

Eswar Krishnan, MD

Is a pIND meeting always a prerequisite for success, or is it sometimes a bottleneck?

Jul 16 •

Eswar Krishnan, MD

mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs

CAR-T Illustration.

Jul 14 •

Eswar Krishnan, MD

Can PD-1 Agonists Halt Sudden Death in Athletes with Hypertrophic Cardiomyopathy?

In February 2025, the sudden death of 22-year-old Portuguese soccer player Diogo Jota during a match stunned the sports world.

Jul 14 •

Eswar Krishnan, MD

Internal Talent Drives PoC Success

Biotech Triallist Newsletter No. 1

Jul 10 •

Eswar Krishnan, MD

Type 5 Diabetes: For CMOs and CSOs

Jul 7 •

Eswar Krishnan, MD

B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs

Jul 6 •

Eswar Krishnan, MD

Why I Believe B-cell Engagers are a Game Changer for Lupus

Jul 4 •

Eswar Krishnan, MD

Interleukin-6 and Cardioimmunology: For CMOs and CSOs

A short podcast

Jul 3 •

Eswar Krishnan, MD

Alt+Ctrl+Del of Immune Memory

Measles can be worse than some chemo protocols

Jul 2 •

Eswar Krishnan, MD

Herbal Hope for Breast Cancer

Cromolyn Sodium's Unexpected Role in Cancer Immunotherapy

Jul 2 •

Eswar Krishnan, MD

"Pill Penalty" and Portfolio Prioritization*: For Biotech CMOs and CSOs

*There are loopholes, apparently

Jul 2

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts